IL-7- and IL-15-mediated TCR sensitization enables T cell responses to self-antigens

Journal of Immunology

Volumn 190, Issue 4, 2013, Pages 1416-1423

  Deshpande, Pratima ^a,b   Cavanagh, Mary M ^a,b   Le Saux, Sabine ^a,b   Singh, Karnail ^c   Weyand, Cornelia M ^a,b   Goronzy, Jörg J ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; GASTRIN RELEASING PEPTIDE; INTERLEUKIN 15; INTERLEUKIN 7; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; SOS PROTEIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTOPENIA; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SENSITIZATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL;

AUTOANTIGENS; CELL DIFFERENTIATION; CELLS, CULTURED; DNA-BINDING PROTEINS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; INTERLEUKIN-15; INTERLEUKIN-7; LYMPHOCYTE ACTIVATION; MAP KINASE SIGNALING SYSTEM; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SON OF SEVENLESS PROTEINS; SOS1 PROTEIN; T-LYMPHOCYTE SUBSETS; UP-REGULATION;

EID: 84873532350     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201620     Document Type: Article

References (63)

1. Sfikakis, P. P. 2010. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr. Dir. Autoimmun. 11: 180-210.
2. Woodrick, R. S., and E. M. Ruderman. 2011. Safety of biologic therapy in rheumatoid arthritis. Nat. Rev. Rheumatol. 7: 639-652.
3. Singh, J. A., G. A. Wells, R. Christensen, E. Tanjong Ghogomu, L. Maxwell, J. K. Macdonald, G. Filippini, N. Skoetz, D. Francis, L. C. Lopes, et al. 2011. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. (2):CD008794.
4. Hill, J. A., S. Southwood, A. Sette, A. M. Jevnikar, D. A. Bell, and E. Cairns. 2003. Cutting edge: the conversion of arginine to citrulline allows for a highaffinity peptide interaction with the rheumatoid arthritis-associated HLADRB1 0401 MHC class II molecule. J. Immunol. 171: 538-541.
5. Goronzy, J. J., and C. M. Weyand. 2009. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res. Ther. 11: 249.
6. Singh, K., P. Deshpande, S. Pryshchep, I. Colmegna, V. Liarski, C. M. Weyand, and J. J. Goronzy. 2009. ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis. J. Immunol. 183: 8258-8267.
7. Cope, A. P., R. S. Liblau, X. D. Yang, M. Congia, C. Laudanna, R. D. Schreiber, L. Probert, G. Kollias, and H. O. McDevitt. 1997. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J. Exp. Med. 185: 1573-1584.
8. Bryl, E., A. N. Vallejo, C. M. Weyand, and J. J. Goronzy. 2001. Down-regulation of CD28 expression by TNF-alpha. J. Immunol. 167: 3231-3238.
9. Koetz, K., E. Bryl, K. Spickschen, W. M. O'Fallon, J. J. Goronzy, and C. M. Weyand. 2000. T cell homeostasis in patients with rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 97: 9203-9208.
10. McInnes, I. B., J. al-Mughales, M. Field, B. P. Leung, F. P. Huang, R. Dixon, R. D. Sturrock, P. C. Wilkinson, and F. Y. Liew. 1996. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 2: 175-182.
11. Boyman, O., C. Krieg, D. Homann, and J. Sprent. 2012. Homeostatic maintenance of T cells and natural killer cells. Cell. Mol. Life Sci. 69: 1597-1608.
12. Sprent, J., and C. D. Surh. 2012. Interleukin 7, maestro of the immune system. Semin. Immunol. 24: 149-150.
13. Pickens, S. R., N. D. Chamberlain, M. V. Volin, R. M. Pope, N. E. Talarico, A. M. Mandelin, II, and S. Shahrara. 2011. Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 63: 2884-2893.
14. McInnes, I. B., B. P. Leung, R. D. Sturrock, M. Field, and F. Y. Liew. 1997. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factoralpha production in rheumatoid arthritis. Nat. Med. 3: 189-195.
15. Halvorsen, E. H., E. Strønen, H. B. Hammer, G. L. Goll, L. M. Sollid, and O. Molberg. 2011. Interleukin-15 induces interleukin-17 production by synovial T cell lines from patients with rheumatoid arthritis. Scand. J. Immunol. 73: 243-249.
16. van Roon, J. A., K. A. Glaudemans, J. W. Bijlsma, and F. P. Lafeber. 2003. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann. Rheum. Dis. 62: 113-119.
17. Borger, P., H. F. Kauffman, D. S. Postma, and E. Vellenga. 1996. IL-7 differentially modulates the expression of IFN-gamma and IL-4 in activated human T lymphocytes by transcriptional and post-transcriptional mechanisms. J. Immunol. 156: 1333-1338.
18. Mehrotra, P. T., A. J. Grant, and J. P. Siegel. 1995. Synergistic effects of IL-7 and IL-12 on human T cell activation. J. Immunol. 154: 5093-5102.
19. Fleischmann, R., M. Cutolo, M. Genovese, E. Lee, K. Kanik, S. Sadis, C. Connell, D. Gruben, S. Krishnaswami, G. Wallenstein, et al. 2012. Phase IIB dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 64: 617-629.
20. Kremer, J. M., S. Cohen, B. E.Wilkinson, C. A. Connell, J. L. French, J. Gomez-Reino, D. Gruben, K. S. Kanik, S. Krishnaswami, V. Pascual-Ramos, et al. 2012. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 64: 970-981.
21. Kierstead, L. S., E. Ranieri, W. Olson, V. Brusic, J. Sidney, A. Sette, Y. L. Kasamon, C. L. Slingluff, Jr., J. M. Kirkwood, and W. J. Storkus. 2001. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br. J. Cancer 85: 1738-1745.
22. Li, Q. J., J. Chau, P. J. Ebert, G. Sylvester, H. Min, G. Liu, R. Braich, M. Manoharan, J. Soutschek, P. Skare, et al. 2007. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129: 147-161.
23. Altan-Bonnet, G., and R. N. Germain. 2005. Modeling T cell antigen discrimination based on feedback control of digital ERK responses. PLoS Biol. 3: e356.
24. Morgan, A. W., W. Thomson, S. G. Martin, A. M. Carter, H. A. Erlich, A. Barton, L. Hocking, D. M. Reid, P. Harrison, P. Wordsworth, et al; Yorkshire Early Arthritis Register Consortium; UK Rheumatoid Arthritis Genetics Consortium. 2009. Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. Arthritis Rheum. 60: 2565-2576.
25. Adema, G. J., A. J. de Boer, A. M. Vogel, W. A. Loenen, and C. G. Figdor. 1994. Molecular characterization of the melanocyte lineage-specific antigen gp100. J. Biol. Chem. 269: 20126-20133.
26. Phan, G. Q., C. E. Touloukian, J. C. Yang, N. P. Restifo, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, C. A. Seipp, L. J. Freezer, et al. 2003. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J. Immunother. 26: 349-356.
27. Boykevisch, S., C. Zhao, H. Sondermann, P. Philippidou, S. Halegoua, J. Kuriyan, and D. Bar-Sagi. 2006. Regulation of ras signaling dynamics by Sosmediated positive feedback. Curr. Biol. 16: 2173-2179.
28. Chakraborty, A. K., J. Das, J. Zikherman, M. Yang, C. C. Govern, M. Ho, A.Weiss, and J. Roose. 2009. Molecular origin and functional consequences of digital signaling and hysteresis during Ras activation in lymphocytes. Sci. Signal. 2: pt2.
29. Isomäki, P., M. Panesar, A. Annenkov, J. M. Clark, B. M. Foxwell, Y. Chernajovsky, and A. P. Cope. 2001. Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex at the cell surface. J. Immunol. 166: 5495-5507.
30. Gringhuis, S. I., E. A. Papendrecht-van der Voort, A. Leow, E. W. Nivine Levarht, F. C. Breedveld, and C. L. Verweij. 2002. Effect of redox balance alterations on cellular localization of LAT and downstream T-cell receptor signaling pathways. Mol. Cell. Biol. 22: 400-411.
31. Bryl, E., A. N. Vallejo, E. L. Matteson, J. M. Witkowski, C. M. Weyand, and J. J. Goronzy. 2005. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum. 52: 2996-3003.
32. Powell, J. D., C. G. Lerner, and R. H. Schwartz. 1999. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J. Immunol. 162: 2775-2784.
33. Seder, R. A., R. N. Germain, P. S. Linsley, and W. E. Paul. 1994. CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production. J. Exp. Med. 179: 299-304.
34. + T cells. J. Exp. Med. 195: 1533-1539.
35. Kanegane, H., and G. Tosato. 1996. Activation of naive and memory T cells by interleukin-15. Blood 88: 230-235.
36. + memory cell pool. J. Clin. Invest. 115: 1177-1187.
37. + T cells. J. Exp. Med. 195: 1515-1522.
38. Sun, J. C., S. M. Lehar, and M. J. Bevan. 2006. Augmented IL-7 signaling during viral infection drives greater expansion of effector T cells but does not enhance memory. J. Immunol. 177: 4458-4463.
39. McInnes, I. B., and J. A. Gracie. 2004. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr. Opin. Pharmacol. 4: 392-397.
40. Goldrath, A. W., C. J. Luckey, R. Park, C. Benoist, and D. Mathis. 2004. The molecular program induced in T cells undergoing homeostatic proliferation. Proc. Natl. Acad. Sci. USA 101: 16885-16890.
41. Calzascia, T., M. Pellegrini, A. Lin, K. M. Garza, A. R. Elford, A. Shahinian, P. S. Ohashi, and T. W. Mak. 2008. CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc. Natl. Acad. Sci. USA 105: 2999-3004.
42. Seddon, B., and R. Zamoyska. 2002. TCR and IL-7 receptor signals can operate independently or synergize to promote lymphopenia-induced expansion of naive T cells. J. Immunol. 169: 3752-3759.
43. Cho, B. K., V. P. Rao, Q. Ge, H. N. Eisen, and J. Chen. 2000. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J. Exp. Med. 192: 549-556.
44. Goldrath, A. W., L. Y. Bogatzki, and M. J. Bevan. 2000. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J. Exp. Med. 192: 557-564.
45. Goronzy, J. J., and C. M. Weyand. 2003. Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity - catalysts of autoimmunity and chronic inflammation. Arthritis Res. Ther. 5: 225-234.
46. Goronzy, J. J., and C. M. Weyand. 2001. Thymic function and peripheral T-cell homeostasis in rheumatoid arthritis. Trends Immunol. 22: 251-255.
47. King, C., A. Ilic, K. Koelsch, and N. Sarvetnick. 2004. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117: 265-277.
48. Wallis, R. H., K. Wang, D. Dabrowski, L. Marandi, T. Ning, E. Hsieh, A. D. Paterson, J. P. Mordes, E. P. Blankenhorn, and P. Poussier. 2007. A novel susceptibility locus on rat chromosome 8 affects spontaneous but not experimentally induced type 1 diabetes. Diabetes 56: 1731-1736.
49. Goronzy, J. J., and C. M. Weyand. 2012. Immune aging and autoimmunity. Cell. Mol. Life Sci. 69: 1615-1623.
50. Müller, M., S. Wandel, R. Colebunders, S. Attia, H. Furrer, and M. Egger; IeDEA Southern and Central Africa. 2010. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect. Dis. 10: 251-261.
51. Goronzy, J. J., L. Shao, and C. M. Weyand. 2010. Immune aging and rheumatoid arthritis. Rheum. Dis. Clin. North Am. 36: 297-310.
52. Shao, L., H. Fujii, I. Colmegna, H. Oishi, J. J. Goronzy, and C. M. Weyand. 2009. Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis. J. Exp. Med. 206: 1435-1449.
53. Fujii, H., L. Shao, I. Colmegna, J. J. Goronzy, and C. M. Weyand. 2009. Telomerase insufficiency in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 106: 4360-4365.
54. Zhao, X., N. L. Okeke, O. Sharpe, F. M. Batliwalla, A. T. Lee, P. P. Ho, B. H. Tomooka, P. K. Gregersen, and W. H. Robinson. 2008. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res. Ther. 10: R94.
55. Law, S. C., S. Street, C. H. Yu, C. Capini, S. Ramnoruth, H. J. Nel, E. van Gorp, C. Hyde, K. Lau, H. Pahau, et al. 2012. T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res. Ther. 14: R118.
56. Berglin, E., L. Padyukov, U. Sundin, G. Hallmans, H. Stenlund, W. J. Van Venrooij, L. Klareskog, and S. R. Dahlqvist. 2004. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res. Ther. 6: R303-R308.
57. Rantapää-Dahlqvist, S., B. A. de Jong, E. Berglin, G. Hallmans, G. Wadell, H. Stenlund, U. Sundin, and W. J. van Venrooij. 2003. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48: 2741-2749.
58. Nielen, M. M., D. van Schaardenburg, H. W. Reesink, R. J. van de Stadt, I. E. van der Horst-Bruinsma, M. H. de Koning, M. R. Habibuw, J. P. Vandenbroucke, and B. A. Dijkmans. 2004. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50: 380-386.
59. Deane, K. D., C. I. O'Donnell, W. Hueber, D. S. Majka, A. A. Lazar, L. A. Derber, W. R. Gilliland, J. D. Edison, J. M. Norris, W. H. Robinson, and V. M. Holers. 2010. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 62: 3161-3172.
60. Stefanová, I., B. Hemmer, M. Vergelli, R. Martin, W. E. Biddison, and R. N. Germain. 2003. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat. Immunol. 4: 248-254.
61. Singh, K., P. Deshpande, G. Li, M. Yu, S. Pryshchep, M. Cavanagh, C. M. Weyand, and J. J. Goronzy. 2012. K-RAS GTPase- and B-RAF kinasemediated T-cell tolerance defects in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 109: E1629-E1637.
62. Das, J., M. Ho, J. Zikherman, C. Govern, M. Yang, A. Weiss, A. K. Chakraborty, and J. P. Roose. 2009. Digital signaling and hysteresis characterize ras activation in lymphoid cells. Cell 136: 337-351.
63. Kremer, J. M., B. J. Bloom, F. C. Breedveld, J. H. Coombs, M. P. Fletcher, D. Gruben, S. Krishnaswami, R. Burgos-Vargas, B. Wilkinson, C. A. Zerbini, and S. H. Zwillich. 2009. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60: 1895-1905.